Hyfinity Investments

Immunowake is a biotechnology company that focuses on identifying new therapies for patients who do not respond to existing immunotherapies. Immunotherapy involves harnessing the body’s immune system to identify and kill cancer cells in the same way pathogens are identified and targeted. Recent breakthroughs in cancer immunotherapy have demonstrated that powerful anti-tumor responses can be achieved by activating antigen-specific T-cells.

InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equipped with global-level top-notch know-how and efficient execution capabilities.

Founded in 2020, Cargene Biopharma is a preclinical-stage biopharmaceutical company developing innovative oligonucleotide therapeutics for liver fibrosis and ophthalmic disorders, with operations in Singapore, USA and China. Cargene uses proprietary platforms backed by novel biology and chemistry insights, Cargene aims to improve quality of life for millions of patients worldwide through creating highly specific, stable and potent nucleic acid-based medicines for the treatment of a broad range of diseases.

Carcell Biopharma is a pre-clinical biotech company. Carcell Biopharma develops cell and gene therapy products with an innovative cross-border business model.

The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.

Beijing Surrey is a technology company founded by an industry elite active in China's medical equipment. Relying on the core technology of the new generation of flexible continuum robotic arm, running through the implementation paradigm of many types of clinical minimally invasive surgery, and harnessing the powerful system design and integration capabilities, Beijing Shurui is committed to becoming the first independent independent research and development, production and sales in China.

Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from Chinese Academy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China.

ipharmacare offers clinically rational drug use support and monitoring management. The clinically rational drug use management system is in line with the PDCA cycle management model. For inquiries, email, telephone numbers, and addresses are available on their website.